ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other best stocks that stole the show last week.

ImmunityBio saw its share prices increase by 18.4 percent week-on-week, with the performance primarily owed to the Food and Drug Administration’s (FDA) green light for the company to expand the access of its Anktiva treatment to patients with solid tumors.

Earlier last week, ImmunityBio, Inc. (NASDAQ:IBRX) received the approval of the FDA to expand its Cancer BioShield platform, anchored by Anktiva, to treat lymphopenia in adult patients with refractory or relapsed solid tumors, independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherapy, radiation, or immunotherapy.

To date, there are no approved treatments for lymphopenia, a depletion of critical lymphocytes responsible for immunogenic cell death, specifically natural killer cells, killer CD8+ T cells and CD4+ with memory T cells.

A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.

Following the announcement, the company earned a “buy” recommendation and a price target of $8 from investment firm HC Wainwright, representing a 154-percent upside from its closing price of $3.15 on Friday.

Overall, IBRX ranks 15th on our list of best stocks that stole the show last week. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.